ReVivo Medical announces two new spine experts to its Board Of Advisors

768

ReVivo Medical has announced that two spinal and orthopaedic experts are joining its Board of Advisors as the company get ready to recruit for a new clinical study.

Hassan Serhan, former distinguished engineering fellow, senior director, research and technology, at DePuy Synthes Spine, a J&J company, joins the board. Serhan was responsible for spine and orthopaedics, technology evaluation and development for the entire organisation.

He is joined on the ReVivo Medical Advisory Board by Jacob Einhorn, chief technology officer and co-founder at Intrinsic Therapeutics. Einhorn has more than 20 years of experience developing new technologies mostly focused on spine.  He has been responsible for clinical development, commercial marketing, new product development, R&D and regulatory strategy.  His career spans Stryker and Pfizer.

Gary Mittleman, president and CEO of ReVivo Medical, said: “Our current management team is well versed to create new medical devices, develop prototypes, have them tested and conduct clinical trials.  Now, as we prepare to start our clinical trial, we wish to make sure that we are positioning ourselves for what comes later: the commercial arena

“Thus, we have appointed to our Board of Advisors two individuals with a wealth of new product development experience in the medical orthopaedic and spine device space.”

ReVivo Medical is currently developing implantable medical devices for use by surgeons on patients with spinal pathology.  The company expects to begin recruiting for its 50-patient clinical study in second quarter of 2021. The trial is scheduled to take place at the Albany Medical Center and the Cleveland Clinic.  Study participants will receive ReVivo Medical’s next generation design anterior cervical plate and interbody cages used in anterior cervical discectomy and fusion procedures.

Chief medical officer, Darryl DiRisio, said: “Anterior cervical plates and interbody cages are used in over 400,000 surgical procedures each year representing a multi-billion-dollar market. The primary measure of success in these operations is the rapid achievement of bone fusion which thereby stabilises the spine.”

None of ReVivo Medical’s devices are currently cleared for use in the United States.


LEAVE A REPLY

Please enter your comment!
Please enter your name here